Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 4
2004 8
2005 6
2006 6
2007 9
2008 9
2009 11
2010 10
2011 9
2012 10
2013 10
2014 8
2015 8
2016 11
2017 16
2018 8
2019 4
2020 4
2021 5
2022 10
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Results by year

Filters applied: . Clear all
Page 1
Role of 18F-choline and 18F-fluorodeoxyglucose positron emission tomography in combination with magnetic resonance imaging in brachytherapy planning for locally advanced cervical cancer: A pilot study.
Rais F, Boudam K, Ménard C, Beauchemin MC, Oulmoudne N, Juneau D, Leblond A, Barkati M. Rais F, et al. Among authors: menard c. Phys Imaging Radiat Oncol. 2023 Jul 6;27:100467. doi: 10.1016/j.phro.2023.100467. eCollection 2023 Jul. Phys Imaging Radiat Oncol. 2023. PMID: 37497190 Free PMC article.
Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases.
Wong P, Masucci L, Florescu M, Plourde ME, Panet-Raymond V, Pavic M, Owen S, Masson-Coté L, Ménard C, Routy B, Tehfe M, Nelson K, Guilbert F, Boucher O, Keshavarzi S, Blais N, Roberge D. Wong P, et al. Among authors: menard c. Neurooncol Adv. 2023 Mar 1;5(1):vdad018. doi: 10.1093/noajnl/vdad018. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37025758 Free PMC article.
PSMA-PET/CT-Guided Intensification of Radiation Therapy for Prostate Cancer (PSMAgRT): Findings of Detection Rate, Effect on Cancer Management, and Early Toxicity From a Phase 2 Randomized Controlled Trial.
Petit C, Delouya G, Taussky D, Barkati M, Lambert C, Beauchemin MC, Clavel S, Mok G, Paré AG, Nguyen TV, Duplan D, Keu KV, Saad F, Juneau D, Ménard C. Petit C, et al. Among authors: menard c. Int J Radiat Oncol Biol Phys. 2023 Jul 15;116(4):779-787. doi: 10.1016/j.ijrobp.2022.12.055. Epub 2023 Jan 11. Int J Radiat Oncol Biol Phys. 2023. PMID: 36639035 Clinical Trial.
Corrigendum: MRI-guided focal or integrated boost high dose rate brachytherapy for recurrent prostate cancer.
Ménard C, Navarro-Domenech I, Liu ZA, Joseph L, Barkati M, Berlin A, Delouya G, Taussky D, Beauchemin MC, Nicolas B, Kadoury S, Rink A, Raman S, Sundaramurthy A, Weersink R, Beliveau-Nadeau D, Helou J, Chung P. Ménard C, et al. Front Oncol. 2022 Nov 17;12:1084708. doi: 10.3389/fonc.2022.1084708. eCollection 2022. Front Oncol. 2022. PMID: 36465337 Free PMC article.
Acute toxicity and health-related quality of life outcomes of localized prostate cancer patients treated with magnetic resonance imaging-guided high-dose-rate brachytherapy: A prospective phase II trial.
Sanmamed N, Adleman J, Berlin A, Borg J, Lao B, Weersink R, Simeonov A, Rink A, Beiki-Ardakani A, Menard C, Chung P, Helou J. Sanmamed N, et al. Among authors: menard c. Brachytherapy. 2023 Jan-Feb;22(1):58-65. doi: 10.1016/j.brachy.2022.08.015. Epub 2022 Nov 19. Brachytherapy. 2023. PMID: 36414526 Clinical Trial.
143 results